Results 21 to 30 of about 132,293 (166)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Clinical Diabetes and Endocrinology, 2018
Background Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system.
Inbal Uri, Simona Grozinsky-Glasberg
doaj   +1 more source

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management

EJNMMI Physics, 2020
Background After each cycle of [177Lu]-DOTA-TATE peptide receptor radionuclide therapy (PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose to tumors and normal organs.
Alexandre Chicheportiche, Simona Ben-Haim, Simona Grozinsky-Glasberg, Kira Oleinikov, Amichay Meirovitz, David J. Gross, Jeremy Godefroy   +6 more
doaj   +1 more source

Theranostics of Neuroendocrine Tumors [PDF]

Visceral Medicine, 2017
Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for ...
Sze Ting, Lee, Harshad R, Kulkarni, Aviral, Singh, Richard P, Baum   +3 more
openaire   +2 more sources

Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen. [PDF]

PLoS ONE, 2012
BackgroundA large fraction of murine tumors induced by transgenic expression of SV40 large T antigen (SV40 TAg) exhibits a neuroendocrine phenotype. It is unclear whether SV40 TAg induces the neuroendocrine phenotype by preferential transformation of ...
Fritz Ihler, Elena Viviana Vetter, Jie Pan, Robert Kammerer, Svenja Debey-Pascher, Joachim L Schultze, Wolfgang Zimmermann, Georg Enders   +7 more
doaj   +1 more source

Neuroendocrine Tumors of the Breast [PDF]

Archives of Pathology & Laboratory Medicine, 2017
Primary neuroendocrine tumors of the breast are a rare and underrecognized subtype of mammary carcinoma. Neuroendocrine tumors of the breast occur predominately in postmenopausal women. The tumors are subclassified into well-differentiated and poorly differentiated neuroendocrine tumors, and invasive breast carcinoma with neuroendocrine features.
Lauren Elizabeth, Rosen, Paolo, Gattuso
openaire   +2 more sources

Hitherto unseen survival in an ALK‐positive‐patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Clinical Case Reports, 2017
Key Clinical Message Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations ...
Signe Risum, Ulrich Knigge, Seppo W. Langer   +2 more
doaj   +1 more source

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

BMC Cancer, 2019
Background For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which
Carolien M. Beukhof, Tessa Brabander, Francien H. van Nederveen, Marie-Louise F. van Velthuysen, Yolanda B. de Rijke, Leo J. Hofland, Gaston J. H. Franssen, Lideke A. C. Fröberg, Boen L. R. Kam, W. Edward Visser, Wouter W. de Herder, Robin P. Peeters   +11 more
doaj   +1 more source

Awareness of a mesenteric mass as a common manifestation of ileal neuroendocrine tumor

Surgical Case Reports, 2020
Omori et al. reported a case of multiple liver metastases originating from synchronous double cancer of “primary mesenteric neuroendocrine tumor” and rectal cancer.
Yosuke Kasai, Eric K. Nakakura
doaj   +1 more source

Emerging role of substance and energy metabolism associated with neuroendocrine regulation in tumor cells

Frontiers in Endocrinology, 2023
Cancer is the second most common cause of mortality in the world. One of the unresolved difficult pathological mechanism issues in malignant tumors is the imbalance of substance and energy metabolism of tumor cells.
Yingying Liu, Yingying Liu, Renjun Gu, Murong Gao, Yangwa Wei, Yu Shi, Xu Wang, Yihuang Gu, Yihuang Gu, Xin Gu, Hongru Zhang   +10 more
doaj   +1 more source

Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms

Journal of Translational Medicine
Background Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare. Hypoxia and lipid metabolism-related gene acetyl-CoA synthetase 2 (ACSS2) is involved in tumor progression, but its role in pNENs is not revealed.
Danyang Gu, Mujie Ye, Guoqin Zhu, Jianan Bai, Jinhao Chen, Lijun Yan, Ping Yu, Feiyu Lu, Chunhua Hu, Yuan Zhong, Pengfei Liu, Qibin He, Qiyun Tang   +12 more
doaj   +1 more source